| September 2010 | ||||||
|---|---|---|---|---|---|---|
| S | M | T | W | T | F | S |
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | ||
Monthly Archives
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
October 2008
September 2008
August 2008
July 2008
June 2008
April 2008
Complete Archives
Most recent entries
SpectraScience Provides Corporate Update and Outlook
SpectraScience appoints Sheldon L. Miller Esq. to its Board of Directors
SpectraScience Receives Notification of Pending Issuance of Two Patents
SpectraScience Retains Quorum Consulting
SpectraScience to Exhibit at Digestive Disease Week in New Orleans
SpectraScience Has Second Unannounced Inspection by FDA
SpectraScience’s Jim Hitchin Featured in MDDI Magazine Article
Health Radio - Interview with CEO, Jim Hichin
Professor Andreas Stallmach Chooses WavSTAT(R) Optical Biopsy System for Early Cancer Detection
SpectraScience CEO Jim Hitchin Speaks to Blogtalkradio About Better Cancer Screening Diagnostics
SpectraScience, Inc. Selects CWR & Partners as Its Public Relations Agency of Record
SpectraScience Forms Advisory Board - Governor Tommy Thompson to be Chairman
SpectraScience Releases Shareholder Newsletter
SpectraScience Engages European Contract Research Organization to Manage Clinical Trials
SpectraScience Awarded Japanese Patent 4361683 for Its Optical Biopsy Forceps System
News
Professor Andreas Stallmach Chooses WavSTAT(R) Optical Biopsy System for Early Cancer Detection
Feb 03, 2010
SAN DIEGO, Feb. 2 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC BulletinBoard: SCIE), a SanDiego based medical device company, announced today thatDr. AndreasStallmach, Department of Internal Medicine II, Divisionof Gastroenterology, Hepatology and Infectious Disease, Friedrich SchillerUniversity of Jena, Germany has selected the WavSTAT Optical Biopsy System for earlydetection of pre-cancers and cancers during colonoscopy procedures.
Professor Stallmach said, "Colon cancer is one of the mostfrequent malignant disorders these days, and, especially in patients withInflammatory Bowel Diseases (IBD), surveillance strategies are of majorimportance. A reliable identification of precancerous lesions is one the mostimportant challenges in GI endoscopy because early detection and treatment arethe most effective measures to prevent advanced cancer. In IBD patients thedifferentiation between pre-malignant and inflammatory lesions can bedifficult; therefore, we are looking forward to using the WavSTAT opticalbiopsy system in these patients."
SpectraScience VP for Sales and Marketing, Michel Vaudry, said, "The WavSTAT can provide physicians, who otherwiserely on the naked eye and experience, with a much more objective cancerscreening tool that will increase their success rate, saving more lives andreducing healthcare costs overall. When the WavSTAT is used in the colonfor IBD (which includes Crohn's disease and ulcerative colitis), the number ofphysical biopsies can be reduced from about 60 to only a few. Thus reducingrisk and procedure time from more than an hour to 20 minutes with less sedationand a better chance to find neoplasia. At the same time, the number ofOptical biopsies performed to find pre-cancerous tissues is for the most partunlimited. More than a million people have IBD in the EU."
Using the principle of Laser Induced Fluorescence (LIF),diseased or cancerous tissue fluoresces differently compared to normal healthytissue. Diseased tissue has reduced fluorophors which, when analyzed by aspecialized detector, can indicate with high sensitivity that the cells arebecoming dysplastic, a precursor to cancer. During colonoscopy, a smallfiber-optic probe is directed by the clinician to touch the suspicious tissue. Depressinga foot switch directs low powered, safe laser light into the tissue. Thelaser shuts off and the tissue fluorescence light is directed back up the samefiber optic probe to a specialized detector. The system's computeranalyzes the detector's output and, within seconds, displays a RED or GREENlight on a screen. A GREEN light means the tissue is "normal"with 96% sensitivity. Where a flat polyp is suspect, multiple uses of theoptical fiber and the RED light may assist the clinician in determining the marginof the "suspect" tissue and remove all of it in the same procedure.
SpectraScience holds approximately 60 patents worldwide thathave been issued or are pending on its WavSTAT® Optical Biopsy System and LUMA®Cervical Imaging Systems. These devices are used to quickly assess tissueto help determine if it is normal, pre-cancerous, or cancerous. The WavSTAT andLUMA Systems are approved by the FDA for detecting pre-cancerous and canceroustissue in the colon and cervix, respectively. An evaluation of theWavSTAT for detection of pre-cancers in the throat ("Barrett'sesophagus") is currently underway.
Forward-LookingStatements
This news release contains forward-looking statements within themeaning of Section 27A of the Securities Act of 1933, as amended, and Section21E of the Securities Exchange Act of 1934, as amended. These forward-lookingstatements involve risks and uncertainties that may cause SpectraScience'sactual results to differ materially from results discussed in forward-lookingstatements. Readers are urged to carefully review and consider the variousdisclosures made by SpectraScience in this news release, it's most recent Form10-K and in SpectraScience's other reports filed with the Securities andExchange Commission ("SEC") that attempt to advise interested partiesof the risks and factors that may affect SpectraScience's business. Theseforward-looking statements are qualified in their entirety by the cautions andrisk factors filed by SpectraScience in its annual report on Form 10-K andother documents.
AboutSpectraScience, Inc.
SpectraScience is a San Diego basedmedical device company that designs, develops, manufactures and marketsspectrophotometry systems capable of determining whether tissue is normal,pre-cancerous or cancerous, without physically removing tissue from the body.The WavSTAT Optical Biopsy System uses light to optically scan tissue andprovide the physician with an immediate analysis. With FDA approval for sale inthe U.S. and the CE Mark for the European Union, the WavSTAT System is thefirst commercially available product that incorporates this innovativetechnology for clinical use. The Company's LUMA imaging technology has receivedFDA approval for a non-invasive optical system that is proven to more effectivelydetect cervical cancer precursors than conventional methods available in themarket today.
About FriedrichSchiller University of Jena
Friedrich Schiller University of Jena, Germany is a public research university located in Jena, Thuringia,Germany. The University was established in 1558 and counts among the ten oldestUniversities in Germany.
Contact:
SpectraScience, Inc.
Jim Hitchin, Chief Executive Officer
(858) 847-0200 x201
Hayden Communications
Investor Relations
Todd Pitcher
(858) 518-1387